[TS-1/CDDP therapy for advanced gastric cancer as neoadjuvant chemotherapy]

Gan To Kagaku Ryoho. 2002 Oct;29(10):1823-8.
[Article in Japanese]

Abstract

Five patients with inoperable advanced gastric cancer were treated with combination chemotherapy of TS-1 and cisplatin (CDDP). TS-1 of 80-120 mg/body/day was orally administered for 3 weeks followed by 2 drug-free weeks, and 60 mg/m2/day of CDDP was venally administered on Day 8. It was possible to evaluate all 5 patients for response and toxicity. Only low grade toxicities (Grade 1 or 2) of leukocytopenia, neutrocytopenia, anemia, nausea, diarrhea and stomatitis were seen. Four of 5 patients achieved a partial response, for a response rate of 80.0%. Stomach, liver, lymph node and peritoneal tumors responded to TS-1/CDDP. TS-1/CDDP therapy produces a high response in cases of gastric cancer, and it is useful as a neoadjuvant chemotherapy.

Publication types

  • English Abstract

MeSH terms

  • Aged
  • Anemia / chemically induced
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cisplatin / administration & dosage
  • Cisplatin / adverse effects
  • Drug Administration Schedule
  • Drug Combinations
  • Female
  • Humans
  • Leukopenia / chemically induced
  • Lymphatic Metastasis
  • Male
  • Middle Aged
  • Nausea / chemically induced
  • Neoadjuvant Therapy
  • Oxonic Acid / administration & dosage
  • Oxonic Acid / adverse effects
  • Preoperative Care
  • Pyridines / administration & dosage
  • Pyridines / adverse effects
  • Stomach Neoplasms / drug therapy*
  • Stomach Neoplasms / pathology
  • Tegafur / administration & dosage
  • Tegafur / adverse effects

Substances

  • Drug Combinations
  • Pyridines
  • S 1 (combination)
  • Tegafur
  • Oxonic Acid
  • Cisplatin